LECIP-ARCONTIA
9.12.2020 10:02:07 CET | Business Wire | Press release
A modern standard device for e-ticketing – the EMV Level 2 Certified LECIP Validator “LV-700” provides public transport authorities with great access to contactless ticketing. The state-of-the-art validator is compliant with VDV-KA and a great enhancement to the end-to-end ticketing solutions from the IVU.suite. LECIP Arcontia AB has agreed to supply IVU Traffic Technologies AG with the LV-700 validator as an integrated part of their IVU.suite product line-up.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201209005021/en/
LECIP ARCONTIA AB and IVU Traffic Technologies AG have concluded a non-exclusive partnership on the distribution of LECIP’s on-board validator “LV-700” which IVU will offer as part of their integrated, one-stop solution IVU.suite. Being EMV L1/L2 compliant, LV-700 will provide a wide variety of payment solutions as an important device of contactless ticketing solutions.
The LV-700 series is designed for fast and smooth cashless and contactless payment with a high-speed processor and large capacity memory for demanding ticket data processing. Contactless payment by using credit cards has become very popular around the globe, preventing crimes such as skimming, and making payment more convenient and secure.
Within the IVU.suite, the IVU.validator-branded LV-700 will play an important role supporting the end-to-end ticketing solutions IVU.fare and IVU.ticket as well as the driver operated on-board computer IVU.ticket.box. By enabling the customers to make quick and uncomplicated cashless payments, the IVU.validator takes some of the pressure from the driver and makes boarding faster.
“As we are migrating our platform to Linux we are excited to be partnering with LECIP Arcontia and start implementing their LV-700 in our upcoming projects,” says Henrik Benner, Head of Equipment Development at IVU Traffic Technologies AG. “Thanks to its VDV-KA compliance and its future proof technology, the validator is a great tool for a more contactless future, and we are looking forward to introducing it to our customers.”
LECIP ARCONTIA AB, a subsidiary of LECIP HOLDINGS CORPORATION (TOKYO: 7213) of Gifu, Japan, operates globally to deliver contactless smart card products and solutions for Automated Fare Collection System (AFC). We develop and distribute smart card readers and terminals used in over 40 countries. Our focus is to deliver reliable, high quality contactless smart card products, and implement software services featuring the latest technology and market requirements in e-ticketing and payment.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201209005021/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
Andreas Goppelt Appointed Managing Director of OrphaCare29.4.2026 10:27:00 CEST | Press release
OrphaCare, a global specialist for the development and marketing of medical devices for drug delivery and part of the AOP Health Group, has appointed Andreas Goppelt as its new Managing Director, succeeding Georg Fischer. In this role, the seasoned medical device expert will focus on broadening the company’s strategic scope and driving its next phase of growth. OrphaCare plays a key role in supporting AOP Health’s integrated therapies approach, and the Group’s long-term expansion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429303533/en/ Portrait Andreas Goppelt, Managing Director OrphaCare (copyright: AOP Health/Studio Koekart) Andreas Goppelt brings more than 25 years of leadership experience across MedTech, biotechnology and the pharmaceutical industry. He has a proven track record of driving innovation, scaling global organizations, and delivering growth in highly regulated healthcare environments. In his new role,
The Jury Has Been Announced for the Third Edition of the Reply AI Film Festival, Dedicated to the Best Short Films Generated With Artificial Intelligence29.4.2026 10:00:00 CEST | Press release
Gabriele Salvatores, together with Rob Minkoff, Catherine Hardwicke, Jed Weintrob, Christina Lee Storm, Nils Hartmann, Guillem Martinez Roura, Filippo Rizzante, Giacomo Mineo, Brian Welk and Denise Negri, will judge the short films in competition based on creativity, production quality and the use of Artificial Intelligence. Reply [EXM, STAR: REY], an international group specialized in creating new business models enabled by AI and long committed to guiding younger generations in exploring emerging technologies, presents the jury of the third edition of the Reply AI Film Festival, the international competition aimed at creatives, directors, and filmmakers who want to challenge themselves in producing short films created using Artificial Intelligence tools. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429288361/en/ “Imaginatio Nova” is the theme of the 2026 edition, an invitation to explore a new phase of imagination, wh
Bregal Milestone Announces Majority Growth Investment in CoreGo, a Leading European Open-Loop Payment and Event Technology Company29.4.2026 10:00:00 CEST | Press release
Investment follows over 98% annual growth and supports CoreGo’s continued market expansion Bregal Milestone, a leading European software growth private equity firm, today announced a majority strategic growth investment in CoreGo Oy ("CoreGo" or the "Company"), a leading provider of open-loop payments and integrated technology solutions for festivals, sports events, and venues across Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427991105/en/ Founded in Helsinki in 2015 by Hannu Elomaa and CTO Nikoteemu Väänänen, CoreGo has built one of Europe's most differentiated open-loop payment infrastructure and event technology businesses. Serving approximately 250 customers across the Nordics and DACH region, the Company delivers an integrated showtime-critical suite of solutions through CoreGo Cloud, unifying payments, access, networks, and data into a single real-time operating system. CoreGo’s in-house private network
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom